ProShare Advisors
CTSO icon

ProShare Advisors’s Cytosorbents Corp CTSO Stock Holding History

ProShare Advisors’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,697
Closed -$81K – 2068
2021
Q2 		$81K Sell
10,697
-278
-3% -$2.34K ﹤0.01% 2315
2021
Q1 		$95K Buy
+10,975
New +$105K ﹤0.01% 2170

Other funds holding CTSO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ProShare Advisors's CTSO Position: Q3 2021 in Review

ProShare Advisors sold out of Cytosorbents Corp (CTSO) in Q3 2021, closing a stake of 10,697 shares — an estimated $81K sold.

ProShare Advisors first reported a position in CTSO in Q1 2021 and held it in 2 quarters. The position peaked at $95K in Q1 2021. 96 funds tracked by Wall St. Rank hold CTSO as of Q3 2021.

  • ProShare Advisors reported no remaining Cytosorbents Corp position as of Q3 2021 after selling out during the quarter.
  • ProShare Advisors sold 10,697 Cytosorbents Corp shares in Q3 2021, an estimated $81K.
  • ProShare Advisors first reported a position in Cytosorbents Corp in Q1 2021 and held it in 2 quarters.
  • ProShare Advisors's Cytosorbents Corp position peaked at $95K in Q1 2021.
  • 96 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q3 2021.

Based on ProShare Advisors's 13F filing for Q3 2021, filed 12 Nov 2021.